Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)

<h4>Objectives</h4> <p>o evaluate the efficacy of etanercept and methotrexate as monotherapies and as combination therapy in subjects with active psoriatic arthritis (PsA).</p> <h4>Methods</h4> <p>he Study of Etanercept and Methotrexate in Combination or as...

Полное описание

Библиографические подробности
Главные авторы:	Mease, P, Gladman, D, Samad, A, Coates, L, Liu, L, Aras, G, Collier, D, Chung, J
Формат:	Journal article
Язык:	English
Опубликовано:	BMJ Publishing Group 2018

Схожие документы

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
по: Coates, L, и др.
Опубликовано: (2020)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
по: Helliwell, PS, и др.
Опубликовано: (2022)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
по: Mease, PJ, и др.
Опубликовано: (2019)

Methotrexate in psoriasis and psoriatic arthritis
по: Coates, L, и др.
Опубликовано: (2020)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
по: Nash, P, и др.
Опубликовано: (2020)

Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
по: Coates, LC, и др.
Опубликовано: (2021)

Should methotrexate have any place in the treatment of psoriatic arthritis?
по: Ye, W, и др.
Опубликовано: (2019)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
по: Taylor, P, и др.
Опубликовано: (2022)

Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PSA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
по: Coates, LC, и др.
Опубликовано: (2022)

Screening/referral strategies for the early recognition of psoriatic arthritis (PsA) among patients with psoriasis: results of a GRAPPA survey
по: Song, K, и др.
Опубликовано: (2023)

Considerations for the definition of remission criteria in psoriatic arthritis
по: Mease, P, и др.
Опубликовано: (2017)

Classification and outcome measures for psoriatic arthritis
по: Leung, Y, и др.
Опубликовано: (2018)

Sex-specific challenges in patients with psoriatic arthritis (PsA): preliminary results from a systematic literature review (SLR)
по: Coates, LC, и др.
Опубликовано: (2021)

Measuring outcomes in psoriatic arthritis
по: Ogdie, A, и др.
Опубликовано: (2020)

Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
по: McGagh, D, и др.
Опубликовано: (2020)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
по: Ogdie, A, и др.
Опубликовано: (2023)

Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting
по: Holland, R, и др.
Опубликовано: (2018)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
по: Coates, L, и др.
Опубликовано: (2019)

Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis—study protocol for the MONITOR-PsA study, a trials within cohorts study design
по: Rombach, I, и др.
Опубликовано: (2021)

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept
по: Choy, E, и др.
Опубликовано: (2007)

Psoriatic arthritis
по: FitzGerald, O, и др.
Опубликовано: (2021)

Etanercept for the treatment of rheumatoid arthritis.
по: Lethaby, A, и др.
Опубликовано: (2013)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
по: Gladman, DD, и др.
Опубликовано: (2018)

Usage of C-reactive protein testing in the diagnosis and monitoring of psoriatic arthritis (PsA): results from a real-world survey in the USA and Europe
по: Ogdie, A, и др.
Опубликовано: (2022)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
по: Coates, L, и др.
Опубликовано: (2017)

Etanercept for the treatment of rheumatoid arthritis.
по: Blumenauer, B, и др.
Опубликовано: (2003)

Etanercept for the treatment of rheumatoid arthritis
по: Blumenauer, B, и др.
Опубликовано: (2004)

The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes
по: De Marco, G, и др.
Опубликовано: (2017)

Treat-to-target in PsA: methods and necessity
по: Dures, E, и др.
Опубликовано: (2020)

Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire
по: Coates, LC, и др.
Опубликовано: (2020)

What should be the primary target of ‘treat to target’ in PsA?
по: Coates, L, и др.
Опубликовано: (2018)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
по: Tillett, W, и др.
Опубликовано: (2017)

The road to personalised medicine in psoriatic arthritis
по: White, JPE, и др.
Опубликовано: (2021)

COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
по: Purcaru, O, и др.
Опубликовано: (2010)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
по: Coates, L, и др.
Опубликовано: (2017)

Psoriatic arthritis: prospects for the future
по: Hackett, S, и др.
Опубликовано: (2022)

Ethical issues in a TwiCs study in early PsA
по: Coates, L, и др.
Опубликовано: (2017)

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
по: Coates, LC, и др.
Опубликовано: (2023)

Identification of psoriatic arthritis in patients with psoriasis
по: Coates, LC, и др.
Опубликовано: (2023)

Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept
по: Kavanaugh, A, и др.
Опубликовано: (2005)